Review decision - July 2009

Review of NICE Technology Appraisal Guidance Nos 103/ 134/ 146; on the use of etanercept and efalizumab for the treatment of adults with psoriasis, infliximab for the treatment of psoriasis and adalimumab for the treatment of psoriasis

The above guidance’s were scheduled for an update in the multiple technology appraisal programme following a review proposal process. The decision to update the above guidance as one MTA was taken because there is new 3-year efalizumab efficacy and safety data that required consideration by the Appraisal Committee. In February 2009 the marketing authorisation for efalizumab was suspended.

Following the suspension, the institute’s guidance executive revisited this decision and has agreed to defer the review of technology appraisal guidance’s 103, 134, 146, until the originally proposed early 2010. At this time the evidence base will again be assessed to ascertain the need for a review of the guidance.

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.